Products for Research Use Only
RegisterLogin

NL13

CAT: 0804-HY-162895Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162895Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth[1].
UNSPSC
12352005
Target
Akt; Apoptosis; Caspase; CDK; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nl13.html
Smiles
ClC1=C(/C=C2CN(C(CC)=O)C/C(C\2=O)=C\C3=CC=CC=C3Cl)C=CC=C1
Molecular Formula
C22H19Cl2NO2
Molecular Weight
400.30
References & Citations
[1]Qiao X, et al. NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models. Br J Pharmacol. 2024 Aug 14.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
T89925-01NL13

Popular Products